PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMolgramostim
Molgramostim
Molgramostim is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AA: Colony stimulating factors
— L03AA03: Molgramostim
HCPCS
No data
Clinical
Clinical Trials
2198 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228—C85.91921113
Prostatic neoplasmsD011471—C61—3—3—6
NeoplasmsD009369—C8021—1—4
Autologous transplantationD014182—————123
NeutropeniaD009503—D70———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.0—91—313
LymphomaD008223—C85.9141—27
Crohn diseaseD003424EFO_0000384K50143——7
MelanomaD008545———11——2
Aplastic anemiaD000741—D61.9—11——2
AnemiaD000740EFO_0004272D64.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470—C92.035———7
LeukemiaD007938—C9533———5
Myeloid leukemiaD007951—C9222———4
Myelodysplastic syndromesD009190—D4613———3
Hodgkin diseaseD006689—C81—3———3
Breast neoplasmsD001943EFO_0003869C50—2———2
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—12———2
Type 1 diabetes mellitusD003922EFO_0001359E1012———2
Hematopoietic stem cell transplantationD018380———1——12
Plasma cell neoplasmsD054219———1——12
Show 14 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematologic neoplasmsD019337——1————1
Fallopian tube neoplasmsD005185——1————1
Ovarian epithelial carcinomaD000077216——1————1
Parkinson diseaseD010300EFO_0002508G201————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lymphoproliferative disordersD008232Orphanet_2442D47.9————11
ParaproteinemiasD010265—D47.2————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMolgramostim
INNmolgramostim
Description
Molgramostim is a recombinant granulocyte macrophage colony-stimulating factor which functions as an immunostimulator.
Classification
Protein
Drug classcolony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF); colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2109134
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDB321AL142J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 512 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
17 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use